Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Topical ALT-2074 for Chronic Plaque Psoriasis
NCT00782613Phase 2Terminated
- Sponsor
- Synvista Therapeutics, Inc.
- Start
- Nov 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of alt-2074 in plaque psoriasis, sponsored by Synvista Therapeutics, Inc. Primary endpoint: Efficacy of topical ALT-2074 at 28 days. Started Nov 2008; status: terminated.
02
Drugs
alt-2074
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00782613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00782613.